<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00773240</url>
  </required_header>
  <id_info>
    <org_study_id>GT-18</org_study_id>
    <nct_id>NCT00773240</nct_id>
  </id_info>
  <brief_title>A Phase III Trial Assessing the Pharmacodynamic Effect and the Tolerability of Grazax Treatment</brief_title>
  <official_title>A Phase III Trial Assessing the Pharmacodynamic Effect and the Tolerability of Grazax Treatment Initiated in the Grass Pollen Season in Subjects With Seasonal Grass Pollen Induced Rhinoconjunctivitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ALK-Abelló A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ALK-Abelló A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study assess the pharmacodynamic effect and the tolerability of Grazax treatment
      initiated in the grass pollen season in subjects with seasonal grass pollen induced
      rhinoconjunctivitis
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacodynamics - Immunological assessments</measure>
    <time_frame>Pre- and post treatment</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">276</enrollment>
  <condition>Grass Pollen Allergy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Grazax</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Grazax</intervention_name>
    <description>1 tablet, 75,000 SQ-T, daily during the trial period</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>1 placebo tablet, matching the active treatment, daily during the trial period</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Positive skin prick test to Phleum pratense

          -  Positive IgE to Phleum pratense

          -  signed informed consent

          -  A clinical history of moderate to severe persistent rhinoconjunctivitis symptoms

        Exclusion Criteria:

          -  No uncontrolled asthma in the past 12 months

          -  No history of an IgE mediated systemic reaction due to food, insect venom, any kind of
             medication or induced by exercise, where there are symptoms both from the skin and the
             respiratory system with or without hypotension

          -  No history of an IgE mediated systemic reaction due to food, insect venom, any kind of
             medication or induced by exercise, where there are symptoms both from the skin and the
             respiratory system with or without hypotension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kim Simonsen, MD</last_name>
    <role>Study Director</role>
    <affiliation>ALK-Abelló A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ALK-Abello A/S, Bøge alle 6-8</name>
      <address>
        <city>Hørsholm</city>
        <zip>DK-2970</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2008</study_first_submitted>
  <study_first_submitted_qc>October 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2008</study_first_posted>
  <last_update_submitted>August 27, 2011</last_update_submitted>
  <last_update_submitted_qc>August 27, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 30, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

